Parenteral nutrition additive shortages: the short-term, long-term and potential epigenetic implications in premature and hospitalized infants. by Hanson, Corrine K. et al.
University of Nebraska Medical Center 
DigitalCommons@UNMC 
Journal Articles: Medical Nutrition Medical Nutrition 
12-1-2012 
Parenteral nutrition additive shortages: the short-term, long-term 
and potential epigenetic implications in premature and 
hospitalized infants. 
Corrine K. Hanson 
University of Nebraska Medical Center, ckhanson@unmc.edu 
Melissa Thoene 
The Nebraska Medical Center, mthoene@nebraskamed.com 
Julie Wagner 
Alegent Health Bergan Mercy Medical Center 
Dean Collier 
University of Nebraska Medical Center, dcollier@unmc.edu 
Kassandra Lecci 
University of Nebraska Medical Center, klecci@nebraskamed.com 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unmc.edu/sahp_nutrition_articles 
 Part of the Medical Nutrition Commons 
Recommended Citation 
Hanson, Corrine K.; Thoene, Melissa; Wagner, Julie; Collier, Dean; Lecci, Kassandra; and Anderson-Berry, 
Ann, "Parenteral nutrition additive shortages: the short-term, long-term and potential epigenetic 
implications in premature and hospitalized infants." (2012). Journal Articles: Medical Nutrition. 1. 
https://digitalcommons.unmc.edu/sahp_nutrition_articles/1 
This Article is brought to you for free and open access by the Medical Nutrition at DigitalCommons@UNMC. It has 
been accepted for inclusion in Journal Articles: Medical Nutrition by an authorized administrator of 
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu. 
Authors 
Corrine K. Hanson, Melissa Thoene, Julie Wagner, Dean Collier, Kassandra Lecci, and Ann Anderson-Berry 
This article is available at DigitalCommons@UNMC: https://digitalcommons.unmc.edu/sahp_nutrition_articles/1 






Parenteral Nutrition Additive Shortages: The Short-Term, 
Long-Term and Potential Epigenetic Implications in Premature 
and Hospitalized Infants 
Corrine Hanson 
1,
*, Melissa Thoene 
2
, Julie Wagner 
3
, Dean Collier 
4
, Kassandra Lecci 
2




1 School of Allied Health Professionals, University of Nebraska Medical Center, Omaha,  
NE 984045, USA 
2 Pharmacy and Nutrition Care Services, Nebraska Medical Center, Omaha, NE 984045, USA;  
E-Mails: mthoene@nebraskamed.com (M.T.); klecci@nebraskamed.com (K.L.) 
3 Alegent Health Bergan Mercy Medical Center, 7500 Mercy Road, Omaha, NE 68124, USA;  
E-Mail: Julie.wagner@alegent.org 
4 College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 986045, USA;  
E-Mail: dcollier@unmc.edu 
5 College of Pediatrics, University of Nebraska Medical Center, Omaha, NE 981205, USA;  
E-Mail: alanders@unmc.edu 
* Author to whom correspondence should be addressed; E-Mail: ckhanson@unmc.edu;  
Tel.: +1-402-559-3658; Fax: +1-402-559-7565. 
Received: 12 October 2012; in revised form: 29 November 2012 / Accepted: 30 November 2012 / 
Published: 7 December 2012 
 
Abstract: Nutrition support practitioners are currently dealing with shortages of parenteral 
nutrition micronutrients, including multivitamins (MVI), selenium and zinc. A recent 
survey from the American Society of Enteral and Parenteral Nutrition (ASPEN) indicates 
that this shortage is having a profound effect on clinical practice. A majority of 
respondents reported taking some aggressive measures to ration existing supplies. Most 
premature infants and many infants with congenital anomalies are dependent on parenteral 
nutrition for the first weeks of life to meet nutritional needs. Because of fragile health and 
poor reserves, they are uniquely susceptible to this problem. It should be understood that 
shortages and rationing have been associated with adverse outcomes, such as lactic 
acidosis and Wernicke encephalopathy from thiamine deficiency or pulmonary and skeletal 
development concerns related to inadequate stores of Vitamin A and D. In this review, we 
will discuss the current parenteral shortages and the possible impact on a population of 
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very low birth weight infants. This review will also present a case study of a neonate who 
was impacted by these current shortages. 
Keywords: TPN; premature infant; nutrient deficiencies; neonate 
 
1. Introduction  
Product shortages in the healthcare system can have a significant impact on the care provided to 
patients. In the case of premature or ill infants, high nutrient needs and a lack of nutrient stores make 
the appropriate administration of nutrition essential. At birth, the clamping of the umbilical cord 
immediately disrupts the delivery of nutrients from the placenta, which places these infants into a 
situation that makes adequate provision of nutrients extremely important and challenging. Though the 
preferred method of feeding, enteral feedings are often delayed in the premature infant due to the 
fragility and medical complications associated with prematurity. Management of co-morbid 
conditions, such as patent ductus arteriosis, chronic lung disease and feeding intolerance frequently 
involve restriction of fluids and delays in enteral feeding advancement. As a result, these cases usually 
remain dependent on parenteral nutrition (PN) for the first few weeks of life; however, those with 
complications, such as necrotizing enterocolitis, may require sole PN for much longer time periods. In 
the infant with congenital anomalies, such as gastroschisis, trachea-esophageal fistula or bowel 
disease, feedings may not be feasible for weeks or even months. There is growing evidence that 
inadequate nutrition in the first few weeks of life results in growth failure and poor long-term 
neurodevelopmental outcomes [1,2]. Due to concern for current shortages of parenteral nutrition (PN) 
micronutrient additives, the purpose of this paper is to review the potential effect of these shortages on 
premature and newborn infants and to present a case study of nutrient deficiency resulting from  
this shortage.  
2. Current Shortages and TPN Management Strategies  
According the American Society for Enteral and Parenteral nutrition (ASPEN), all PN products, 
aside from dextrose and water, have been in short supply at some point since the spring of 2010  
(see Table 1) [3]. At the time of this writing, a number of PN products continue to be unavailable or in 
short supply. The current status of these and other drug products can be accessed at the Food and Drug 
Administration web site [4]. 
Table 1. Parenteral Shortages 2010–2012.  
Amino Acids Ascorbic Acid Calcium Chloride 
Calcium Gluconate Chromium Copper 
Cyanocobalamin Fat Emulsions L-cysteine 
Magnesium Sulfate Multivitamins (MVI) Phytonadione (vitamin K) 
Potassium Acetate Potassium Phosphate Selenium 
Sodium Acetate Sodium phosphate Trace Elements 
Vitamin A Zinc  
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ASPEN has provided timely and comprehensive advice to clinicians for dealing with PN product 
shortages. Recommendations for conserving products during shortages of electrolytes, vitamins and 
minerals are included in Table 2. 
Table 2. ASPEN Recommendations for Conservation of PN Products. 
1. Consider oral or enteral administration 
2. Prioritize patients, saving supplies for those most vulnerable patients 
3. Eliminate adding injectable electrolytes/minerals to enteral nutrition products 
4. Minimize the use of additives to daily maintenance IV fluids 
5. Reevaluate replacement algorithms or treatment protocols 
6. Carefully evaluate alternative supplies of individual and multiple electrolyte products that are 
available, including standardized, commercially available PN products 
In a recent survey conducted by ASPEN, 25% of respondents stated their hospitals are in short 
supply of pediatric multi-dose products, and 28% indicated they are in short supply of single-dose 
products, such as selenium. When asked what actions were being employed in response to these 
shortages, 70% reported giving multivitamins (MVI) only three times per week, 28% were giving half 
the recommended dose daily, 27% were giving no MVI and 9% were giving adult MVI to pediatric 
patients [3].  
Product shortages are not new and have historically been documented to cause morbidity and 
mortality. The omission of vitamins from PN has been associated with death as far back as 1989, when 
three people at a large university medical center died from refractory lactic acidosis caused by 
receiving thiamine-deficient PN [5]. In 1997, three additional patients receiving thiamine-free TPN 
due to a national shortage developed lactic acidosis, and later, in 1998, a case report of Wernicke 
encephalopathy and beriberi due to a multivitamin shortage was published [6]. Due to the historical 
documentation of such adverse outcomes in adults, we sought documentation of the potentially adverse 
effects in high-risk, premature infants.  
3. Nutritional Needs of Preterm Infants and Potential Effect of Shortages of PN Components  
Proteins and Amino Acids: Per kilogram, premature infants have among the highest protein needs of 
any population during the lifecycle. Adequate protein provision of up to 4–4.5 g/kg/day is required for 
very low birthweight infants to match intrauterine accretion rates and to promote appropriate 
growth [7,8]. Adequate growth during Neonatal Intensive Care Unit (NICU) hospitalization is essential 
to reduce the risk for negative outcomes associated with growth restriction, including chronic lung 
disease, cerebral palsy, neurological impairment and rehospitalization after discharge [3,9]. The early 
administration of parenteral protein helps to offset the nutritional deficits that begin with preterm birth 
and continue throughout the infant’s hospitalization [10]. Early administration of PN that meets protein 
goals has been associated with improvements in both short-term [11] and long-term growth [1]. In 
contrast, infants not receiving early administration of amino acids have been found to have suboptimal 
head growth at 18 months of age [1]. Restrictions in head circumference growth are especially 
concerning, given the association between poor head growth and decreased neurodevelopmental 
outcomes [12]. Likewise, goal provisions of both protein and energy during the first week of life may 
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positively influence 18-month developmental outcomes [13]. Furthermore, shortages of individual 
amino acids can have a profound effect on premature infant outcomes. For example, supplementation 
of neonatal PN with cysteine has been associated with improved nitrogen balance, which may support 
appropriate growth for both weight and head circumference [14,15]. The addition of cysteine may also 
help to lower the pH of the PN mixture. This allows increased amounts of calcium and phosphorus to 
be provided with a decreased risk for mineral precipitation, further promoting adequate bone 
mineralization and growth [16]. Consequently, shortages of amino acid formulations impacting early 
and adequate provision of protein in this population can have significant long-term ramifications. 
Lipids: Fat provision is essential for life, but most specifically for premature infants to promote 
normal growth and development. Fat is the most calorically-dense nutrient and aids in the development 
of cells, the eye and the brain. Without lipid provision to PN-dependent infants, essential fatty acid 
deficiency (EFAD) develops quickly as there are reports as early as the second day of life [17]. EFAD 
may result in failure to thrive, dermatitis, thrombocytopenia, susceptibility to infection and poor would 
healing [17]. Fat-free PN as the primary source of nutrition may further result in suboptimal calorie 
provision and associated growth restriction. Increased total caloric intake in the first week of life has 
been associated with improved Bailey MDI scores in a preterm infant population [13]. 
Minerals: In addition to macronutrient shortages, micronutrient shortages have the potential to 
significantly impact the health of infants. One PN additive that is commonly used among the 
premature infant population is calcium gluconate. Although higher in aluminum content than other 
available PN calcium salts, calcium gluconate is often the additive of choice due to its favorable 
solubility curves, allowing for higher calcium and phosphorus administration. Like protein, calcium 
and phosphorus needs in premature infants remain high. Approximately 80% of total body calcium, 
phosphorus and magnesium at birth are accrued within the last trimester of pregnancy. Consequently, 
infants born prematurely have inadequately mineralized bones and require higher weight-based 
provisions of calcium and phosphorus compared to infants born at term [8]. Adequate magnesium 
provision is also necessary to promote bone growth, as hypomagnesaemia may hinder calcium 
absorption. In addition, many common medications used for NICU infants can decrease calcium and 
magnesium absorption, including diuretics, steroids and anti-convulsants [8,18]. It has been  
well-documented that premature infants receiving inadequate amounts of calcium and phosphorus 
from PN have higher incidences of osteopenia and elevated levels of serum alkaline phosphatase, 
which may indicate poor bone mineralization and rapid bone turnover [19]. Clinical manifestations of 
poorly mineralized bone will vary depending on the degree of bone mineralization. Bone fractures may 
develop in these infants as a result and may negatively affect the stability of the chest wall, which can 
lead to atelectasis or an increased risk of chronic lung disease [14].  
Trace Elements: Only two trace elements are recommended on the initial day of PN; zinc and 
selenium. Other trace elements are not thought to be needed until after two weeks of age [14]. Zinc is a 
cofactor in more than 300 metabolic processes and supports protein and nucleic acid synthesis, 
immune function, gene expression and growth. Two-thirds of the total body zinc is transferred from 
mother to fetus during the last trimester of pregnancy and serum levels of zinc decline progressively in 
infants on zinc-free PN [20]. As a result, ill neonates are at a high risk of developing zinc deficiency if 
adequate supplementation cannot be provided. Additionally, most commercially-available trace 
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element formulations contain insufficient zinc to meet the needs of the preterm infant. Therefore, 
supplemental zinc must be added to PN, creating an additional mechanism for shortages.  
Selenium is a component of glutathione peroxidase, a compound which protects against free radical 
injury. Premature infants are often exposed to high levels of oxygen and resulting oxidative stress. It 
has been speculated, though not proven, that selenium could be an important contributing factor in the 
pathogenesis of disorders, such as bronchopulmonary dysplasia [21]. Most of the placental transfer of 
selenium occurs after the 36th week of gestation [20]; hence, most premature infants will be born 
selenium-depleted. Serum selenium concentrations have been shown to decrease quickly in infants 
treated for respiratory distress syndrome who receive selenium-free or selenium-deficient PN [22]. A 
2009 Cochrane review of selenium supplementation suggested that the currently recommended dose of 
selenium (2 µg/kg/day) for preterm infants receiving parenteral nutrition is inadequate to maintain 
selenium concentrations, so a dose of 3 µg/kg/day may be more appropriate to achieve concentrations 
found in healthy breast-fed infants [23]. As current shortages make it difficult to provide even the 
previously recommended amounts, implementing new evidence-based recommendations for increased 
nutrient dosing becomes nearly impossible. 
Inadequate provision of many other trace elements also poses nutritional risks for premature infants. 
For example, both rapid growth and limited stores make premature infants at risk for copper 
deficiency, which can result in osteoporosis, neutropenia or hypochromatic anemia [17]. Like zinc and 
selenium, accretion of these nutrients occurs primarily during the last trimester of pregnancy, so 
adequate provision is essential. 
Vitamins: Premature infants require higher amounts of most vitamins when compared to term 
infants, due to increased nutrient losses or increased requirements for growth. Recent studies have 
documented nutrient deficiencies, specifically vitamin D deficiency, are highly prevalent in preterm 
births [24–27]. Vitamin D supplementation during infancy is associated with increased bone mass in 
childhood [28]. Consequently, deficiency and inadequate supplementation may result in rickets or 
craniotabes [29]. Recent research has also expanded our understanding of vitamin D status during 
infancy to include health benefits beyond bone status. Poor vitamin D status during early infancy is 
now thought to be associated with other negative health outcomes, such as type 1 diabetes [30,31], and 
pulmonary problems, such as respiratory tract infections or wheezing later in childhood [32–34]. The 
current recommendation for parenteral vitamin D intake is 400 IU/day [8] which is the amount 
included in 5 mL in most pediatric PN MVI formulations. Concerning, however, is that PN pediatric 
MVI dosing is weight-based according to the manufacturer instructions; so many low birth weight 
infants receive less than 5 mL (400 IU Vitamin D) daily. These dosing practices, combined with 
product shortages, may make adequate administration of vitamin D challenging in infants dependent 
on PN. Monitoring the vitamin D status of newborns is additionally challenging, as 25(OH)D levels 
are not an accurate marker of vitamin D status in the newborn population. In 2006, Singh et al. showed 
that a biologically inactive C-3 epimer of vitamin D is present in high levels in the bloodstream of 
infants up to one year of age and may lead to an overestimation of vitamin D status in infants and 
concerns regarding vitamin D overdosing in others [35].  
Administration of vitamin E is recommended immediately after birth in premature infants, as some 
older studies suggest a reduction in incidence and severity of intraventricular hemorrhage. A plasma 
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target of >1 mg/dL by 24 h of life, and 2 mg/dL by three days of life has been recommended to reduce 
IVH [14,36,37]. These levels should be attainable with the administration of current PN MVI 
formulations, which would provide 2.8 mg/kg/day of vitamin E if given daily. However, limiting the 
amount of MVI provided to premature infants, as many institutions are now being forced to do, could 
negatively impact serum levels.  
Vitamin A is necessary in premature infants for normal lung growth and for maintaining the 
integrity of the respiratory epithelial track. Preterm infants are born with essentially no hepatic 
reserves of Vitamin A, so levels of vitamin A at birth are reflectively low [38]. Therefore, Vitamin A 
needs to be provided consistently from PN to promote adequate intake. However, a 2011 study 
demonstrated that despite a policy to introduce intravenous-lipid supplemented PN by day of life two, 
only 11% of infants consistently met the recommended daily intake of vitamin A during the first two 
weeks of life [39]. Considering inadequate provision despite the best efforts, it remains concerning that 
many PN-dependent infants are receiving reduced MVI dosing due to current shortages. The role of 
vitamin A in preventing neonatal chronic lung disease has consistently been documented, including 
evidence that intramuscular supplementation of vitamin A in extremely low birthweight infants 
improves respiratory outcomes [38,40]. A meta-analysis of low birthweight infants demonstrated that 
either enteral or parenteral supplementation with vitamin A reduced the risk of both death and oxygen 
requirement at one month of age, and the risk of oxygen requirement at 36 weeks corrected gestational 
age [38]. This practice may be limited, since intramuscular injections are considered painful; however, 
current product shortages of the vitamin injections would inhibit this practice from being initiated in 
NICUs targeting bronchopulmonary dysplasia (BPD). In addition to its role in lung integrity, vitamin 
A appears critical in the development of ocular photoreceptors. During the third trimester of 
pregnancy, the ocular content of rhodopsin (of which vitamin A is an essential component) increases 
10-fold [39]. For the NICU hospitalized infant, an adequate substrate in the form of vitamin A needs to 
be available to support this process in the extrauterine environment. Recommended PN administration 
of vitamins and minerals discussed above are given in Table 3. Vitamin levels provided by current 
MVI dosing guidelines are provided in Table 4.  
Table 3. Recommended PN Administration of Select Nutrients *. 
 Birth weight <1.5 kg Term Infants 
Calcium 3 mEq/kg/day 2 mEq/kg/day 
Zinc 1000–3000 μg/kg/day 
250 μg/day <3 months 
100 µg/day >3 months 
Selenium 1.3–4.5 μg/kg/day 2.0 μg/day 
Vitamin A 700–1500 IU/day 2300 IU  
Vitamin D 400 IU/day 400 IU/day 
Vitamin E 6–12 IU/kg/day 7 IU/day 
* Adapted from [16]. 
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Table 4. Vitamin Levels Provided by Current Dosing of Pediatric MVI. 
 
Per 1.5 mL MVI 
(<1000 g) 
Per 3.25 mL MVI 
(1001–2500 g) 
Per 5 mL MVI 
(>2500 g) 
Vitamin C (mg) 24 5.2 80 
Vitamin A (IU) 690 1495 2300 
Vitamin D (IU) 120 260 400 
Thiamine (B1) (mg) 0.36 0.78 1.2 
Riboflavin (B2) (mg) 0.42 0.91 1.4 
Pyridoxine (B6) (mg) 0.3 0.65 1 
Niacin (mg) 5.1 11.1 17 
Dexpanthenol (mg) 1.5 3.3 5 
VitaminE (IU) 2.1 4.6 7 
Vitamin K (mg) 0.06 0.13 0.2 
Folic Acid (μg) 42 91 140 
Biotin (μg) 6 13 20 
B12 (μg) 0.3 0.65 1 
Epigenetic Ramifications of Early Neonatal Nutrition: In addition to the acute problems from 
inadequate nutrient provision during the NICU stay, accumulating evidence implies that the early 
prenatal period is critical for influencing disease risk for a range of disorders that may develop later in 
life. There is considerable evidence suggesting that the risk of developing non-communicable diseases 
can be altered by modifying influences of early-life environment, which includes nutritional factors. 
This programming appears to be largely independent of genomic sequences and is likely to be 
mediated by epigenetic mechanisms. Epigenetic programming during development is widely believed 
to have a long-lasting effect on the health of a newborn [41]. Epigenetic changes are modification to 
the DNA, which can be caused by various factors, including the environment, which do not change the 
underlying sequence.  
Studies have demonstrated that infants born prematurely have decreased insulin sensitivity when 
compared with those born at term [42,43]. In one study of preterm vs. term infants and insulin 
sensitivity, all of the infants born prematurely had inadequate protein intake in the first month of life, 
which was proposed as a trigger to an epigenetic modification of genes involved in glucose  
regulation [42]. Supplementation with vitamin D during infancy has been reported to confer protection 
against beta-cell regulated autoimmune disorders [44,45]. A potentially very important activity of 
vitamin D receptor agonists is their capacity to induce in vitro and in vivo tolerogenic dendrite cells, 
which are able to enhance suppressor T-cells that, in turn, inhibit T-cell responses. Failure of tolerance 
mechanisms may lead to auto-reactive T-cell activation and to induction of autoimmune diseases [46]. 
In a birth-cohort study published in 2001, Hypponen et al. found that vitamin D supplementation 
during the first year of life is associated with a lower risk of type-1 diabetes [47]. This prospective 
study followed 12,055 infants born in Finland and collected data in the first year of life regarding 
vitamin D supplementation practices; later in life, data was collected on the diagnosis of type I 
diabetes. At this time in Finland, the recommended level of Vitamin D supplementation for infants was 
2000 IU daily, and infants in the study were classified as follows: receiving daily supplementation of 
less than 2000 IU, within 2000 IU or over 2000 IU. Higher vitamin D supplementation in infancy was 
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associated with a decreased frequency of Type 1 diabetes later in life when adjusted for neonatal, 
anthropometric and social characteristics. Infants who regularly took the recommended dose of 2000 
IU vitamin D per day had a relative risk (RR) of 0.22 (95% CI: 0.05–0.89) compared to those who 
regularly received less than the recommended amount. Children suspected of having rickets during the 
first year of life had a RR of 3.0 (95% CI: 1.0–9.0) compared with those without such a suspicion [31]. 
These results are consistent with the findings of the EURODIAB study in 1999, which was a large 
multicenter and population-based case-control study on early risk factors of childhood onset Type I 
diabetes. Vitamin D supplementation in early infancy to prevent rickets in seven different European 
regions was also associated with a decreased risk for childhood-onset, insulin-dependent diabetes. The 
favorable association with vitamin D supplementation persisted after adjustment for birth weight, 
duration of breast feeding, maternal age and study center [30]. Additionally, vitamin D supplementation 
in infancy has also been associated with a decreased risk of pre-eclampsia later in life [47]. 
Consideration of the potential for early nutrition interventions to have long-term health outcome 
implications is crucial when designing nutrition support regimens for the premature infant population. 
Potential Cost of Shortages: Poor outcomes attributable to PN shortages can quickly become costly 
to both an infant’s health and associated healthcare costs. In 2007, the Journal of Pediatrics compiled 
data regarding health care costs associated with initial hospitalization for premature infants. The data 
clearly showed a monetary cost increase for all premature births compared to term births, but this cost 
was four-to-seven-times higher for low birthweight infants with complications like chronic lung 
disease or intraventricular hemorrhage. Additionally, 15% of all premature or low birthweight infants 
were given a diagnosis of slow growth, malnutrition or small for gestational age. The cost for these 
categorized infants was nearly $450 million [48]. Despite high health care costs, complications 
associated with inadequate nutrition from PN shortages can have a much more devastating toll on 
infant health. Complications, such as intraventricular hemorrhages or developmental delay, may 
impact life-long ability and care requirements. Similarly, chronic diseases pose increased risks for 
infections and infant mortality. Adequate provision of nutrients from PN is essential to help preserve 
the health integrity of these infants, but unfortunately, PN shortages have the potential to do  
the opposite. 
Case Study: At our care facility, one infant on prolonged PN-developed selenium deficiency with 
associated skin symptoms. This infant was born at an estimated gestational age of approximately  
26 weeks with a birth weight of 790 g. The infant developed a bowel perforation within the first few 
weeks of life and required surgery, with a resulting jejunostomy placement. The infant required both 
sole and partial PN for most of his extensive hospital stay, and was approximately four months of age 
when able to take full enteral feedings. Due to current shortages, no selenium was available to add to 
the PN formulation. The infant developed dry, scaly skin and a selenium level was checked around 
three months of life secondary to skin symptoms and recent PN additive shortages. The selenium level 
was reported from the laboratory as 11 μg/L, which is well below the normal range for serum selenium 
of 23–190 μg/L. Conditions, such as macrocytosis and fatal cardiomyopathy, have been reported when 
selenium levels fall below 16 μg/L [23]. Once enteral feedings were established, 25 µg of oral 
selenium was supplemented every other day, because no parenteral selenium was available. By 
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discharge around five months of life, the infant was on calorically-dense full enteral feedings and his 
skin symptoms had resolved, so at this point selenium supplementation was discontinued.  
Potential Solutions: As is evident from Table 2, whenever possible during a shortage of PN 
products, prioritization of resources is crucial in ensuring that the most vulnerable populations receive 
critical products. Additional strategies to potentially maximize the nutrition status of premature infants 
during PN product shortages should be explored. For instance, our care facility was forced to reduce 
pediatric PN MVI to tri-weekly provision to conserve supplies. With the concern for inadequate 
nutrient provision to our extremely and very low birthweight infants, we increased the weight-based 
MVI dosing. For example, infants receiving 1.5 mL of PN MVI would receive 3.25 mL tri-weekly. 
Though this is not a documented strategy, it does allow for a higher administration of nutrients while 
conserving available local resources. 
4. Conclusion  
This review demonstrates the potential short-term and long term epigenetic impacts that current PN 
shortages can have on premature and ill infants. Clinicians must, therefore, make decisions using 
current evidence and clinical judgment to ensure avoidance of poor outcomes in situations where 
adequate administration of all essential nutrients is not possible.  
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